Reuters -- Data showed Roche Holding AG’s MabThera cancer drug reduced the progression of joint damage when used as a first line treatment for rheumatoid arthritis (RA), the Swiss group said on Thursday. Results of the so-called IMAGE study, presented at a European League Against Rheumatism meeting, showed a course of two infusions of MabThera given every 24 weeks can significantly slow damage after one year of treatment.
